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REPORTS ofexperimental tumors resistant to various nucleic acid, amino acid,
and folic acid antagonists used in cancer chemotherapy are now fairly numerous
(Welch, 1959), and several mechanisms of resistance have been demonstrated by
comparing resistant tumors with their corresponding sensitive lines. Much less
work has been done with tumors resistant to alkylating agents. Jackson (1954)
has reported a subline of the Walker rat carcinoma resistant to triethylene mela-
mine (TEM), and Yoshida (1959), a nitromin-resistant subline of the Yoshida rat
ascites sarcoma. Several workers have studied rat tumors (Gorozhansky, 1959 ;
Kurita et al., 1959; Oboshi, 1959) and Ehrlich mouse ascites cells (Inoue et al.,
1958) resistant to nitrogen mustard derivatives.
Mouse ascites tumors are convenient tools for in vivo and in vitro studies on
the mechanism of action of chemotherapeutic agents and on possible differences
between sensitive and resistant cells. It seemed worthwhile to attempt to develop
sublines of mouse ascites tumors resistant to alkylating agents commonly used in
treatment ofhuman leukemias. We wereparticularly interested intestingpossible
differences in nucleic acid metabolism, and used the Ehrlich carcinoma and Sar-
coma 180 (SI80) ascites tumors, since considerable information on their nucleic
acid metabolism was already available (Hartman and Buchanan, 1959). The
effects of two alkvlatina, azents, TEM and busulfan, on these ascites tumors were
investigated, and sublines resistant to TEM were developed by consecutive
passages of tumor cells in animals given intraperitoneal injections of this drug.
MATERIALS AND METHODS
Mice.-Female white Swiss mice, 20-25 g., were obtained from A. R. Schmidt
& Co., Madison, Wisconsin, and were watered and fed Rockland rat diet ad libitum.
Unless otherwise noted, there were 10 mice ofcomparable weight in each experi-
mental group. Survival times were recorded to the nearest halfday.
Transplanatation of tumors.-Ascites tumor cells were transplanted by with-
drawing the ascites fluid from a donor mouse bearing a 7-day tumor growth.
The fluid was centrifuged for 5 minutes in a clinical centrifuge at 1470 x g, the
supernate was decanted, and the cells were diluted 1:20 with isotonic saline. Each
animal received 0-2 ml. of the cell suspension(107 cells).
17.jection ofdrUg8.-Drugs were injected intraperitoneally beginning 24 hours
after tumor implantation, and continued at 24-hour intervals when 3 or 4 injec-
tions were given or at a 48-hour interval when 2 injections were given. Drug dosages of TEM designated A-F in the Tables are as follows: Ag 4 mg./kg., I xMOUSE ASCITES TUMOR RESISTANT TO TEM 343
B . 2 mg./kg., I x ; C, 2 mg./kg., 2 x ; D, I-3 mg./kg., 3 x ; E, I mg./kg., 4 x ;
F) 0-8 mg./kg., 3x. Control groups received injections of saline. Drugs were
dissolved in saline and injected in volumes of 0-2 ml. TEM or 0-5 ml. busulfan.
Solutions of TEM were prepared from thepowder for each series ofinjections and
thus held in the refrigerator not longer than 3 days. TEM was obtained from
Lederle Laboratories and the
" Myleran
" brand of busulfan from Burroughs
Wellcome & Co.
The following dosages ofdrugs were administered in the experiment described
in Table V. 6-Mercaptopurine : 30 mg./kg., 1 x/day for 6 days ; thioguanine
0-5 mg./kg., 2 x/day for 6 days ; azaserine : 0-2 mg./kg., 2 x/day for 6 days
5-fluorouracil : 20 mg./kg., I x/day for 7 days; azauridine : 1-5 mg./kg.; 1 x/day
for 6 days ; amethopterin : 0-25 mg./kg., 1 x/day for 6 days.
Measurement of packed cell volume.-Packed cell volume was measured by
collecting the ascites fluid (containing ascites cells and any infiltrated blood cells)
in a graduated conical tube and centrifuging for 5 minutes in a clinical centrifuge
at 1470 x g.
RES'ULTS
Effect ofbusulfan
Treatment with 20 mg./kg. busulfan at 12-hour intervals for 3-5 days resulted
in survival times equal to those of untreated control groups, and reduced packed
cell volumes of the Ehrlich tumor by about 70 per cent and of the SI80 tumorby
about 50 per cent. Lower dose regimens did not significantly prolong survival
times, and thus no further studies were done with thisdrug.
Effect oftriethylene melamine
Table I shows the effect ofvarious doseregimens ofTEM on Ehrlich and SI80
ascites cells. It was found that 4 mg./kg. body weight was the maximum dose
that could be given in one injection if the animals were to survive as long as
TABLIF, I.-Effectof TEM on Ehrlich and Sarcoma 180 Ascite8 Cells
Treatment* Days survival ml. Packed cell volume
Ehrlich
Control 11-9 ± 1-Ot (7-5-15-5)t 2-7 ± 0-23t (1-3-4-O)l A 14-6 ± 1-0 (10-20-5) 0- 2 ± 0- 09 (0-0-9)
B 16-8 ± 1-4 (10-5-25) 2- 9 ± 0- 36 (0-9-4-0) C§ 12-8 ± 0-7 (8-5-16) 0-1 ± 0-01 (0-0-3)
D§ 16-4 ± 0-9 (10-21-5) 0- 2 ± 0- 08 (0-0-7) E 15- 5 ± 0-5 (13-5-18-5) I- 8 ± O- 23 (O-6-2-5)
F 22- 7 ± 2-4 (13-5-33-5) 2- 2 ± 0- 49 (0-4-4-0)
Sarcoma 180
Control 12-1 ± O- 6 (9-14) 2- 3 + 0-10 (2-0-2-8) A 13-2 ± 1-6 (8-22) 0- 3 ± 0- 08 (0-0-9) B 18-0 ± 1-1 (9-21) 1- 8 ± 0-23 (1-0-3-2) C§ 18- 8 ± O- 7 (8-21) 0-4 ± 0-06 (0-1-0-6)
D 17- 7 ± 1-0 (11-20-5) 0- 3 ± 0- 06 (0-1-0-6)
E 19- 3 ± 1- 2 (16-21-5) 0-6 ± 0- 15 (0- 2-1-7)
* Drug dosages are given in Methods.
t Standard deviation of the mean.
+ Range of values.
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7 days. Ruvidic, Mathe and Bernard (1958) have reported that a single injection
of 5 mg./kg. body weight TEM induced aplasia of the bone marrow in mice with
death ofall animals within 6 days. Survival times ofmicebearing the S180 tumor
were prolonged under all dose regimens except A, and those of mice with the
Ehrlich tumor, by all but C. Therelatively non-toxic treatment F almost doubled
the survival time of mice with the latter tumor.
Eight ofthe micereceiving a total of 4 mg./kg. in 1, 2, and 3 doses (treatments
A, C, D) showed no tumor cells at death (I0-14-5days), but thisdrug concentration
was too toxic for the mice to live indefinitely and be labeled as
" cures ". Since
drug toxicity was a factor in the survival times of animals receiving the higher
doses of TEM, packed cell volumes were also used to compare the effectiveness
of this drug against sensitive lines of ascites cells versus resistant sublines. This
measurement, of course, does not distinguish differences in cell size. When
smears were made at the time of death of the tumor-bearing animals, there were
no noticeable size differences between sensitive line and its resistant sublines.
Ascites cells of treated animals did not differ noticeably from those of untreated
animals when death occurred after about 12 days. When animals died before 10-
12 days with small volumes of tumor cells (i.e., from drug toxicity), the cell popu-
lation was not so homogenous in size, but the variation included both larger and
smaller cells.
Development of subline8 resistant to triethylene melamine
Both Ehrlich and S180 tumors were treated with 4 mg./kg. one time (Treat-
ment A), andpooled cells from several mice were transplanted at intervals of 7 to
21 (usually 14) days. The 14th Ehrlich and 28th S180 transplants were used for
the experiments of Table II. After the 22nd generation, another series was begun
TABLEII.-EffectofTEM on SublinesofA86teS CellsPreviously Treated with TEM
Treatment* Days survival ml. Packed cell volume
Ehrlich Subline Treatment A
Controlt 16
- 6 ± 1
-5t (9-25)§ 2-6 ± 0-18t (1-5-3-2)§
A 15-5 ± 0-5 (12-5-19) 1-1 ± 0-36 (0-1-2-7)
B 12-7 ± 1-7 (8-22-5) 1-0 ± 0-09 (0-8-1-5)
C 18-3 ± 1-6 (10-24) 2-2 ± 0-33 (0-8-4-0)
Sarcoma 180 Subline Treatment A
Control 15-1 ± 1-3 (9-5-21) 2-9 ± 0-32 (1-5-4-5)
A 16-3 ± 1-2 (10-21) 1-1 ± 0-19 (0-2-1-9)
B 15-2 0-7 (14-19) 2-4 0-32 (1-1-4-0)
C 18-5 1-1 (15-26-5) 2-5 0-34 (0-9-4-4)
D 15-7 0-5 (14-19) 2-4 0-41 (0-4-4-1)
F, 17-4 0-7 (15-22) 2-5 0-41 (0-7-4-6)
Sarcoma 180 Subline Treatment D
Control 17-3 ± 0-9 (11-5-20) 2-2 0-18 (1-5-3-0)
A 16-1 + 1-5 (9-5-22) 1-3 0-36 (0-2-4-5)
B 16-9 ± 0-5 (13-18) 3-3 0-24 (2-2-4-5)
C 21-3 ± 1-2 (19-29) 2-6 0-34 (1-2-4-0)
D 18-6 0-6 (16--22) 2-7 0-24 (1-3-3-5)
18-9 1-0 (15-23) 2-6 + 0-28 (1.8-4-1)
Drug dosages are given in Methods.
t Group contained 9 mice.
$ Standard deviation of the mean.
§ Range of values.MOUSE ASCITES TIUMOR RESISTANT TO TEM 345
from these resistant traiisplants to be treated with I-3 mg./kg. 3 times (Treatment
D), a more convenient dose regimen from the standpoint oftoxicity and numbers
of mice to be routinely transplanted. The 4th transplant generation of the S180
Treatment D subline was used in the experiment of Table 11.
A comparison of control groups in Tables I and 11 shows that mice bearing
the resistant sublines had longer survival times. The experiment with the Ehrlich
resistant subline was run at the same time as that with the Ehrlich sensitive line
in Table 1, and average survival times were 16-6 (resistant) and 11-9 (sensitive)
days. Control groups of the 8180 sensitive line and Treatment D subline were run
at the same time as the experiment with the S180 Treatment A subline shown in
Table 11, with the following survival times and packed cell volumes: sensitive,
12-1 ± 1-2 days and 2-4 ± 0-29 ml. ; Treatment D subline, 14-8 ± 0-9 days and
-2-2 ± 0-25 ml. Since packed cell volumes at death did not differ greatly, the
resistant tumors evidently grow more slowly than the sensitive lines.
Treatment B prolonged the average survival times ofmicebearing the sensitive
tumors (Table 1), but not of those bearing the resistant sublines (Table 11).
Treatment C prolonged the average survival times of mice bearing the resistant
S180 sublines 7 but the average packed cell volumes measured at death were much
greater than that of the sensitive line given Treatment C. The data in Table III
TABLE III.-Relative Packed Cells Volumes of Sensitive and Resistant Cells when
Survival Time8were Equal
Line of cells Treatment* Days survival ml. Packed cell volume
Ehrlich Sensitive
None 13- 5, 14 3 3, 3
- 0
C 13- 5, 14 0, <0- 1, 0- I
Ehrlich Subline Treatmei-it A
None 15- 5, 16- 5 I- 5, 2- 8
C 14 3 0, 3
- 4
S180 Sensitive
'Xone 14 2 0, 2 0, 2 2
C 19, 20 O- 2, O- 3, 0 5
D 14, 19, 20 0- 1, 0- 3, 0-2, 0- 3
8180 Sublitie Treatment A
None 15 2 5, 3
- 9
C 15 3 4
D 15 2 1, 2
-4, 3- 8
S180 Subline Treatment, D
None 19, 20 I- 5, 2-2, 2
- 8, 2 0
C 19 2 4, 2 8, 3 2, 4- 0
D 20 2.0, 3 3, 3
-4, 3
- 5
Drug dosages are given in Methods.
have been arranged to show this difference in packed cell volumes. Some values
from mice ofeach subline aregiven to compare control group versus treated groups
with similar survival times, and sensitive versus resistant sublines with similar
survival times. In the latter comparison, it should be remembered that the re-
sistant tumors are slower growing. Treated mice of resistant sublines had cell
volumes equal to or greater than those of their controls, in contrast to results
with sensitive lines.
To determine if the resistance was stable in the absence of TEM, a series was
started from the 27th transplant generation of the S180 Treatment A subline and
carried without thedrug. Tests ofthe 8thtransplantgeneration (TableIV) showed346 ANNA MARIA WILLIAMS AND ELAINE JORANGER
TABLIF, IV.-Effect of TEM on Resistant Subline of Sarcoma 180 Carried Without
TEMfor Eight Transplant Generations
Treatment* Days survival ml. Packed ceR volume
Control 16-7 ± 0-9t (10-20)t 3-1 ± 0-14t (2-4-3-7)t
B 15-9 ± 0-6 (13-5-19) 3-3 ± 0-30 (1-5-5-1)
c 18-9 ± 0-9 (16-5-22) 1-8 ± 0-34 (0-8-3-4)
D 19-1 ± 1-1 (17-27) 3-1 ± 0-31 (2-0-4-5)
* Drug dosages are given in Methods.
t Standard deviation of the mean.
t Range of values.
that the tumor was still resistant, with both the slower growth characteristic and
the proliferation in the presence of TEM shown by the treated resistant subline.
Effect of antimetabolites on S180 cell populations sensitive and resistant to TEM
Table V compares the action of various antimetabolites known to affect
nucleic acid metabolism on the S180 tumors sensitive and resistant to TEM. All
TABLEV.-Effectof VariousAntimeta.bolites on Sarconm 180Ascites-cellPopulations
Sensitive and Resistant to TEM
S180 sensitive to TEM 8180 resistant to TEM
-4--- A
r r
Drug* Days survival ml. Cells Days survival ml. CeUs
Control 11
- 7±O
-6t (9-15)t 2-3±0-25t (1-2-3-5)t. 18-3±0-9 (13-21) 1-4±0-15 (0-5-2-2)
6-Mercaptopurine 13-0±0-9 (8-15) 1-2±0-15 (0-3-1-8) 51-6±3-5 (25-56)§ 0-13±0-09 (0-0-8) [6, Olli
Thioguanine 15-7±1-0 (10-21-5) 1-7±0-37 (0-3-4-1) 56±0 0 [8, 2]
Azaserine . 18-6±0- 6 (13-5-20) 3-9±0-36 (1-6-6-0) 51-6±2- 7 (30-56) 0-17±0-09 (0-0-7) [6, 1]
5-Fluorouracil 18-8±0-8 (13-5-22) 1-8±0-28 (0-5-3-2) 55-2±0-8 (48-56) 0-48±0-30 (0-2-8) [6, 1]
Azauridine 21-4±2-0 (13-34) 1-0±0-24 (0-2-2-4) 39-4 4-8 (19-56) 1-5±0 30 (0-3-5) [2, 0]
Amethopterin 23-3±0-9 (18-27) 1-6±0-39 (0-1-3-5) 41
-4 2
- 7 (30-56) 0-73±0-33 (0-1-8) [2, 0]
Drug dosages are given in Methods.
t Standard deviation of the mean.
t Range of values.
§ Group contained 9 mice.
11 The first figure in brackets is the number of n-jice without ascites cells or solid tumors; the second figure is the
number with no ascites ceRs or fluid but with one solid tumor in the peritoneal cavity.
6 drugs had a greater chemotherapeutic effect on the resistant Treatment A sub-
line, and a number of animals bearing this subline were free of tumor cells when
killed on the 56th day. These have been considered as 56-day survivors in the
calculation of average survival time. A few animals had no ascites cells or fluid
but exhibited a single solid tumor within the peritoneal cavity.
The slower growth of the resistant subline must be considered in evaluating
these results, and since both tumor lines were treated with drug 24 hours after
transplantation, it might be argued that the resistant tumor was in an earlier
stage ofgrowth. However, the relative increase in sensitivity to these antimeta-
bolites displayed by the resistant tumor was not the same for all the drugs.
Thioguanine and 6-mereaptopurine were the least effective drugs, and amethop-
terin and azauridine the most effective, in prolonging survival times of mice
bearing the tumor sensitive to TEM. With the tumor resistant to TEM, thiogu'a-
nine was the most effective drug and amethopterin and azauridine were the least
effective; 6-mercaptopurine was more effective than the latter two drugs.MOUSE ASCITES TUMOR RESISTANT TO TEM 347
DISCUSSION
The only other report of a tumor resistant to TEM of which we are aware is
that of Jackson (1954), who described the development ofWalker carcinosarcoma
solid tumors. These grew after a latent period of about 2 weeks following treat-
ment with 0-2 mg./kg. TEM daily for 8 days. A resistant tumor was maintained
by transplantation with and without drug, and the line carried without drug
was still resistant after about 50 transplant generations. Interestingly, in un-
treated animals the resistant rat tumor grew morerapidly than theoriginal tumor,
in contrast to our resistant tumorwhich grew moreslowly. From various consider-
ations, Jackson concluded that the resistant tumor had arisen from the survival
of a small number of cells which were naturally resistant to TEM, but that the
contribution of the mutagenic effects of the drug remained to beinvestigated.
The present work has demonstrated thefeasibility ofdeveloping mouse ascites
tumors resistant to TEM. We had been primarily interested in obtaining a stable
tumor resistant to this alkylating agent for biochemical studies, and our work
does not bear upon the question of selection or mutation as the mechanism by
which resistance was developed. However, our resistant subhne provides an ex-
ample of a tumor which after treatment with one drug was markedly more sus-
ceptible to certain other drugs. The increased sensitivity of the resistant S180
subline to a number of antimetabolites known to affect nucleic acid metabolism
is best explained by the selection of a population with altered pathways for
nucleic acid biosynthesis, and this supposition is under investigation.
SUMMARY
Sublines oftwo mouse ascites tumors, the Ehrlich carcinoma and Sarcoma 180,
exhibiting resistance to triethylene melamine were developed by consecutive
passage ofcells in mice treated withtriethylene melamine. The change was found
to be heritable, and stable for at least 8 transplant generations in the absence of
the drug. The S180 resistant subline showed increased sensitivity to azaserine,
amethopterin, 5-fluorouracil, azauridine, thioguanine, and 6-mercaptopurine.
Doses of the latter two drugs which prolonged the survival times of the sensitive
subline by less than 35 per cent, with all animals dying, prolonged that of the
resistant subhne by at least 180 per cent, with more than half of the animals free
from tumor cells when killed at 56 days.
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